<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035823</url>
  </required_header>
  <id_info>
    <org_study_id>COMMAND</org_study_id>
    <nct_id>NCT05035823</nct_id>
  </id_info>
  <brief_title>COMMAND Early Feasibility Study (EFS)</brief_title>
  <official_title>Motor NeuroProsthesis to Restore Motor Control for the COMMAND of Digital Devices: An Early Feasibility Study (EFS) of Safety in Subjects With Severe Quadriparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synchron Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synchron Medical, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor&#xD;
      impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning&#xD;
      motor cortex. The purpose of this research is to find out if the MMP device is safe in&#xD;
      humans.&#xD;
&#xD;
      The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor&#xD;
      neurons. The device is designed to restore the transmission of neural signal from the&#xD;
      cerebral cortex utilised for neuromuscular control of digital devices, resulting in a&#xD;
      successful execution of non-mechanical digital commands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Related Adverse Events</measure>
    <time_frame>12 months post implant</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Neurologic Disorder</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Implantation of the motor neuroprosthesis medical device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Motor Neuroprosthesis (MNP)</intervention_name>
    <description>Type of implantable brain computer interface</description>
    <arm_group_label>Single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe quadriparesis&#xD;
&#xD;
          2. Able to give consent&#xD;
&#xD;
          3. Appropriate candidate for neurointerventional procedure&#xD;
&#xD;
          4. Able and willing to access all clinical testing and not impeded by geographical&#xD;
             location&#xD;
&#xD;
          5. Proficient in English&#xD;
&#xD;
          6. Have a study partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active condition resulting in immunosuppression&#xD;
&#xD;
          2. Unsuitable for general anesthesia&#xD;
&#xD;
          3. Anaphylactic allergy to contrast media&#xD;
&#xD;
          4. Allergy to nickel&#xD;
&#xD;
          5. History of pulmonary embolism&#xD;
&#xD;
          6. History of recent deep vein thrombosis&#xD;
&#xD;
          7. Psychiatric or psychological disorder&#xD;
&#xD;
          8. Unable to provide evidence of COVID vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erica Breyman</last_name>
    <phone>212-241-6500</phone>
    <email>erica.breyman@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Ilnicki</last_name>
    <phone>4127802967</phone>
    <email>ilnickima@upmc.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

